Clinical Trials Logo

Clinical Trial Summary

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in Hyperplastic disease of breast patients .


Clinical Trial Description

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule,give three times a day versus placebo in Hyperplastic disease of breast patients .The clinical phase of the study comprises a run-in period,an 3-months double-blind treatment period and a 1-month follow-up period, resulting in 5-months overall duration of the study for each patient. Patients report their breast pain as measured using NRS scale on the subject daily diary。 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04229706
Study type Interventional
Source Tasly Pharmaceutical Group Co., Ltd
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 31, 2019
Completion date January 15, 2023